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Introduction {#sec005}
============

Individuals with end-stage renal disease (ESRD) are at high risk of cardiovascular disease (CVD) mortality\[[@pone.0222547.ref001],[@pone.0222547.ref002]\]. Renal replacement therapy is aimed to reduce this risk. However, in the first months after initiation of hemodialysis (HD) an increased mortality risk\[[@pone.0222547.ref003],[@pone.0222547.ref004]\] related to CVD\[[@pone.0222547.ref001]\] is observed. In contrast, kidney transplant recipients have a lower CVD risk as compared with individuals with ESRD who receive dialysis and remain on the waiting list\[[@pone.0222547.ref005],[@pone.0222547.ref006]\]. Nevertheless, CVD in kidney transplant recipients risk is still higher than that observed in the general population\[[@pone.0222547.ref006]\], reflecting a so-called residual CVD risk\[[@pone.0222547.ref007]\].

Endothelial dysfunction (ED) and low-grade inflammation (LGI) have both been implicated in the adverse CVD risk associated with ESRD\[[@pone.0222547.ref008]--[@pone.0222547.ref010]\]. Indeed, serum biomarkers of ED and LGI are associated with CVD events in ESRD\[[@pone.0222547.ref011]--[@pone.0222547.ref013]\], and may be used for CVD risk stratification in individuals with ESRD. In addition, ED and LGI interact at the renal level and may contribute to the development and progression of renal injury, as elegantly described recently\[[@pone.0222547.ref014]\].

However, to the best of our knowledge, only limited data are available on the course of serum biomarkers of ED and LGI in the transition phase from untreated ESRD to chronic dialysis (*i*.*e*., including assessment of ED and LGI prior and following exposure to dialysis)\[[@pone.0222547.ref015],[@pone.0222547.ref016]\]. In addition, the available studies were restricted to participants on peritoneal dialysis (PD).

Studies on ED and LGI following kidney transplantation are similarly scarce and either examined LGI only or used a single biomarker to assess ED\[[@pone.0222547.ref017]--[@pone.0222547.ref019]\].

More extensive assessment of ED and LGI may provide complementary information as both ED and LGI are heterogeneous concepts, which may not be captured with a single biomarker. For example, ED may involve multiple endothelial functions such as regulation of leukocyte adhesion and regulation of hemostasis.

In view of the above, we, first, examined cross-sectional differences in an extensive panel of serum biomarkers of ED and LGI between individuals with chronic kidney disease (CKD) stage 5 non-dialysis (CKD5-ND; comprising individuals who were scheduled to initiate dialysis or receive a kidney transplant), CKD stage 5 HD (CKD5-HD), CKD stage 5 PD (CKD5-PD) and healthy controls. The serum biomarkers included soluble vascular cellular adhesion molecule 1 (sVCAM-1), E-selectin, P-selectin, thrombomodulin, soluble intercellular adhesion molecule 1 (sICAM-1), soluble intercellular adhesion molecular 3 (sICAM-3), high-sensitivity C-reactive protein (hs-CRP), serum amyloid A (SAA), interleukin 6 (IL-6), interleukin 8 (IL-8), and tumor necrosis factor alpha (TNF-α). Second, we examined the courses of these serum biomarkers during the first six months following initiation of HD and PD, and following kidney transplantation, respectively.

Materials and methods {#sec006}
=====================

Study population and design {#sec007}
---------------------------

This study consisted of a cross-sectional and a longitudinal part, and included participants from three separate observational studies which have been performed in the southern part of the Netherlands and focused on dialysis initiation (HD and PD), kidney transplantation and chronic dialysis (HD and PD), respectively. These studies were conducted between February 2012 and July 2017, between October 2013 and January 2018, and between June 2012 and December 2017, respectively. The methodology of the individual studies has been published previously \[[@pone.0222547.ref020],[@pone.0222547.ref021]\]. A complete overview of in- and exclusion criteria of these studies is also provided in [S1 Methods](#pone.0222547.s003){ref-type="supplementary-material"}.

[S1 Fig](#pone.0222547.s001){ref-type="supplementary-material"} is a flowchart showing the derivation of the cross-sectional study population. For the cross-sectional part, we included baseline data of incident dialysis patients and kidney transplant recipients, and data of prevalent dialysis patients. In addition, we included baseline data of healthy kidney donors and data of healthy controls, which together formed a healthy control group. The cross-sectional analyses were performed in the subpopulation with data on serum biomarkers of ED and LGI. Patients receiving nocturnal HD were excluded from the analyses as a previous study that included participants from the chronic dialysis study has already shown that levels of the measured serum biomarkers of ED and LGI are similar to those in conventional HD \[[@pone.0222547.ref021]\].

Some participants participated in more than one study (*i*.*e*., incident dialysis patients who subsequently received a kidney transplant or were studied as prevalent dialysis patients). Only data from their first study was analyzed.

[S1 Fig](#pone.0222547.s001){ref-type="supplementary-material"} is a flowchart showing the derivation of the longitudinal study population. For the longitudinal part, we included incident HD, incident PD patients and kidney transplant recipients who had complete baseline and follow-up data on serum biomarkers of endothelial dysfunction and low-grade inflammation. Participants who participated in both the study on dialysis initiation and the study on kidney transplantation were included as both dialysis patients and kidney transplant recipients as there was no direct statistical comparison between groups.

Incident HD and PD patients were followed prospectively with assessments at six months after dialysis initiation. Kidney transplant recipients were followed prospectively with assessments at three and six months post-transplantation.

Written informed consent was obtained from each patient prior to participation. The studies were approved by the Ethical Committee (NL43381.068.13, NL33129.068.10, NL35039.068.10) and the Hospital Board of the Maastricht University Medical Center+. All methods were carried out in accordance with relevant guidelines and regulation. In addition, none of the transplant donors were from a vulnerable population and all donors or next of kin provided written informed consent that was freely given.

Renal replacement therapy modalities {#sec008}
------------------------------------

Detailed information on the dialysis treatments applied in both incident and prevalent dialysis patients and the immunosuppressive protocol of kidney transplant recipients are provided in [S1 Methods](#pone.0222547.s003){ref-type="supplementary-material"}.

Study measurements {#sec009}
------------------

### Serum biomarkers of endothelial dysfunction and low-grade inflammation {#sec010}

Blood was collected in sterile 5 ml BD vacutainer SST II Advance tubes. After centrifugation, serum was aspirated and stored at -80°C until analysis. Before analysis, serum samples where thawed and mixed thoroughly.

sVCAM-1, E-selectin, P-selectin, thrombomodulin, sICAM-1, sICAM-3, hs-CRP, SAA, IL-6, IL-8, and TNF-α were measured with a single- or multiplex array detection system based on electro-chemiluminescence technology (Meso Scale Discovery SECTOR Imager 2400, Gaithersburg, Maryland, USA). All measurements were performed in duplicate. Inter-assay and intra‐assay variations for all the markers were \<9%, except the inter-assay variation for E-selectin (10.1%), sICAM-1 (10.2%) and IL-6 (14.0%).

### Other laboratory parameters {#sec011}

Dialysis adequacy (Kt/V) was retrospectively collected from the health record (single-pool Kt/V for HD, weekly Kt/V for PD). In addition, serum creatinine and/or serum β2-microglobulin were measured with routine laboratory measurements at the time of study participation, except for healthy kidney donors and kidney transplant recipients, for whom these data were retrospectively collected from the health record. In controls and in participants with CKD5-ND, GFR was estimated with the CKD-EPI equation based on serum creatinine (eGFR~CKD-EPI~) \[[@pone.0222547.ref022]\]. In participants with CKD5-D, residual GFR was estimated with an equation based on serum β2-microglobulin (eGFR~residual~)\[[@pone.0222547.ref023]\].

### Clinical characteristics {#sec012}

Origin of renal disease was based on the diagnosis as reported in the patient's health record and categorized as nephrosclerosis, glomerulosclerosis, hypertensive nephropathy, renovascular disease, diabetic nephropathy, polycystic kidney disease, IgA nephropathy, glomerulonephritis, other, and unknown. History of diabetes mellitus and cardiovascular disease, and medication use were based on self-report for healthy controls and the health record for patients. Current smoking was based on self-report. Current dialysis modality, history of kidney transplantation, dialysis vintage and residual urine output were collected from the health record. Body mass index (BMI) was calculated as weight divided by height squared. Fluid overload was measured with the Body Composition Monitor (BCM^®^) (Fresenius Medical Care, Bad Homburg, Germany). Office blood pressure was measured with an electronic sphygmomanometer (Omron M4-I, Omron, Japan).

All participants were requested to be in a fasting state during the measurements. For practical reasons not all patients were in fasting state as requested, for example, individuals with diabetes. In participants on HD, study measurements and blood sampling were performed prior to one of their dialysis sessions (the midweek session for prevalent HD patients; either the first, second or third session for incident HD patients and for non-preemptively transplanted patients prior to KTx).

Statistical analyses {#sec013}
--------------------

Characteristics of the study population for the cross-sectional and longitudinal analyses were presented as means with standard deviations (SDs), medians with 25^th^ and 75^th^ percentiles, and numbers with percentages, as appropriate.

Unadjusted post-hoc comparisons of characteristics of participant groups were performed with the independent Student t-test for normally distributed data, Dunn's test for non-normally distributed data and Fisher's exact test for categorical data if a one-way analysis of variance (ANOVA) test, Kruskal-Wallis test and Fisher's exact test, respectively, indicated an overall difference between groups.

Correlations among baseline levels of serum biomarkers of ED and LGI were examined with Spearman's rank correlation coefficients, stratified by participant group.

For the cross-sectional analyses, participants were stratified into controls, CKD5-ND (*i*.*e*., baseline data of incident dialysis patients and future kidney transplant recipients), CKD5-HD and CKD5-PD (*i*.*e*., prevalent dialysis patients including future kidney transplant recipients who were on dialysis at baseline).

Differences in individual serum biomarkers of ED and LGI between CKD5-ND, CKD5-HD, CKD5-PD and controls were evaluated with linear regression analyses to allow adjustment for potential confounders. Levels of serum biomarkers were positively skewed and, therefore, natural log transformed to obtain acceptably normally distributed residuals. The regression coefficients were exponentiated to obtain the ratio of (geometric mean) levels of the serum biomarkers in CKD5-ND, CKD5-HD and CKD5-PD relative to controls and among ESRD groups.

In addition, standardized composite scores (Z-scores) were calculated for ED and LGI and compared across groups with linear regression analyses. The use of composite scores may increase statistical efficiency and reduce the influence of biological and analytical variability \[[@pone.0222547.ref024]\]. For this purpose, levels of each individual biomarker were natural log transformed and standardized. Subsequently, the Z-scores were calculated as the standardized average of the standardized scores of the individual serum biomarkers. The Z-score for ED included sVCAM-1, E-selectin, P-selectin, thrombomodulin, sICAM-1 and sICAM-3, and the Z-score for LGI consisted of hs-CRP, SAA, IL-6, IL-8, TNF-α, sICAM-1 and sICAM-3 \[[@pone.0222547.ref025]\]. The serum biomarkers sICAM-1 and sICAM-3 were included in the Z-scores for both ED and LGI as both are expressed by endothelial cells and leukocytes \[[@pone.0222547.ref025]\].

All linear regression analyses were adjusted for age, sex and diabetes mellitus.

Longitudinal analyses were conducted stratified for incident HD and PD patients, and for kidney transplant recipients. Courses of natural log transformed serum biomarkers of ED and LGI over time following dialysis initiation and kidney transplantation were analyzed with linear mixed models to account for within-person correlations between repeated measurements and missing data. The fixed-effects part contained time as categorical variable (baseline served as reference), and the random-effects parts included a random intercept. The models for incident HD and PD patients also contained an interaction term between time and dialysis modality to test whether courses differ between HD and PD. Models were fitted by restricted maximum likelihood. Regression coefficients were exponentiated to obtain the ratio of (geometric mean) biomarker levels relative to baseline levels.

A two-tailed *P* value \< 0.050 was considered statistically significant, except for interaction analyses for which 0.100 was used as a cut-off.

Analyses were conducted in IBM SPSS Statistics Version 24.0 (IBM Corp., Armonk, NY, USA) and in R Version 3.5.1 with RStudio Version 1.1.456 combined with the packages tidyverse, haven, scales, ggpubr, corrplot and nlme.

Results {#sec014}
=======

Population characteristics---Cross-sectional analyses {#sec015}
-----------------------------------------------------

Thirty-six controls, 43 participants with CKD5-ND, 20 participants with CKD5-HD and 14 participants with CKD5-PD comprised the cross-sectional study population ([Table 1](#pone.0222547.t001){ref-type="table"}; flowchart in [S1 Fig](#pone.0222547.s001){ref-type="supplementary-material"}). In general, participants with CKD5-ND, CKD5-HD and CKD5-PD were more often men and had a worse CVD risk profile than controls.

10.1371/journal.pone.0222547.t001

###### Population characteristics cross-sectional analyses.

![](pone.0222547.t001){#pone.0222547.t001g}

                                                                                   Controls                 CKD5-ND                                             CKD5-HD                                                                                    CKD5-PD
  -------------------------------------------------------------------------------- ------------------------ --------------------------------------------------- ------------------------------------------------------------------------------------------ ----------------------------------------------------------
  *Clinical characteristics*                                                                                                                                                                                                                               
  Age (years)                                                                      57.6 ±12.3               58.8 ±13.9                                          61.4 ±13.6                                                                                 56.9 ±11.8
  Men                                                                              19 (52.8%)               29 (67.4%)                                          14 (70.0%)                                                                                 9 (64.3%)
  Origin of end-stage renal disease:                                                                                                                            [^‡^](#t001fn005){ref-type="table-fn"}                                                     [^‡^](#t001fn005){ref-type="table-fn"}
  Nephrosclerosis                                                                  NA                       6 (14.0%)                                           0 (0.0%)                                                                                   0 (0.0%)
  Glomerulosclerosis                                                               NA                       2 (4.7%)                                            0 (0.0%)                                                                                   0 (0.0%)
  Hypertensive nephropathy                                                         NA                       2 (4.7%)                                            4 (20.0%)                                                                                  4 (28.6%)
  Renovascular disease                                                             NA                       0 (0.0%)                                            1 (5.0%)                                                                                   1 (7.1%)
  Diabetic nephropathy                                                             NA                       2 (4.7%)                                            5 (25.0%)                                                                                  2 (14.3%)
  Polycystic kidney disease                                                        NA                       11 (25.6%)                                          6 (30.0%)                                                                                  0 (0.0%)
  IgA nephropathy                                                                  NA                       2 (4.7%)                                            0 (0.0%)                                                                                   1 (7.1%)
  Glomerulonephritis                                                               NA                       4 (9.3%)                                            2 (10.0%)                                                                                  4 (28.6%)
  Nephrotic syndrome                                                               NA                       6 (14.0%)                                           0 (0.0%)                                                                                   0 (0.0%)
  Other                                                                            NA                       1 (2.3%)                                            2 (10.0%)                                                                                  1 (7.1%)
  Unknown                                                                          NA                       7 (16.3%)                                           0 (0.0%)                                                                                   1 (7.1%)
  History of KTx                                                                   NA                       8 (18.6%)                                           3 (15.0%)                                                                                  3 (21.4%)
  Immunosuppressive therapy in participants with positive history of KTx                                                                                                                                                                                   
   None                                                                            NA                       0 (0.0%)                                            1 (33.3%)                                                                                  1 (33.3%)
   Prednisolone monotherapy                                                        NA                       1 (12.5%)                                           0 (0.0%)                                                                                   0 (0.0%)
   TAC monotherapy                                                                 NA                       4 (50.0%)                                           1 (33.3%)                                                                                  1 (33.3%)
   MMF monotherapy                                                                 NA                       0 (0.0%)                                            1 (33.3%)                                                                                  1 (33.3%)
   TAC/MMF monotherapy (unclear)                                                   NA                       1 (12.5%)                                           0 (0.0%)                                                                                   0 (0.0%)
   Unknown                                                                         NA                       2 (25.0%)                                           0 (0.0%)                                                                                   0 (0.0%)
  First future treatment modality                                                                                                                                                                                                                          
  HD                                                                               NA                       19 (44.2%)                                          NA                                                                                         NA
  PD                                                                               NA                       18 (41.9%)                                          NA                                                                                         NA
  Preemptive KTx                                                                   NA                       6 (14.0%)                                           NA                                                                                         NA
  Non-preemptive KTx                                                               NA                       0 (0%)                                              NA                                                                                         NA
  Dialysis vintage (months)[\*](#t001fn003){ref-type="table-fn"}                   NA                       NA                                                  27 \[22--54\]                                                                              14 \[6--22\] [^¶^](#t001fn006){ref-type="table-fn"}
  Kt/V HD (single-pool)/ PD (weekly)[\*](#t001fn003){ref-type="table-fn"}          NA                       NA                                                  2.2 ±0.1                                                                                   2.3 ±0.7
  Serum creatinine (μmol/L)[\*](#t001fn003){ref-type="table-fn"}                   83 \[75--90\]            579 \[431--720\]                                    722 \[565--829\]                                                                           694 \[495--1106\]
  eGFR~CKD-EPI~ (mL/min/1.73m^2^)[\*](#t001fn003){ref-type="table-fn"}             81.4 ±13.6               8.6 ±3.1[^†^](#t001fn004){ref-type="table-fn"}      NA                                                                                         NA
  eGFR~residual~ (mL/min/1.73m^2^)[\*](#t001fn003){ref-type="table-fn"}            NA                       NA                                                  3.6 \[1.9--4.4\]                                                                           9.3 \[4.7--18.8\] [^¶^](#t001fn006){ref-type="table-fn"}
  Diuresis / Residual urine output[\*](#t001fn003){ref-type="table-fn"}            16 (100%)                38 (100%)                                           15 (75.0%)[^‡^](#t001fn005){ref-type="table-fn"}                                           13 (92.9%)
  Diuresis / Residual urine output (mL/24h)[\*](#t001fn003){ref-type="table-fn"}   1,790 \[1,138--2,352\]   2,000 \[1,700--2,296\]                              1,025 \[15--1,694\]                                                                        1,125 \[288--1,533\]
  Diabetes mellitus                                                                0 (0.0%)                 5 (11.6%)                                           8 (40.0%)[^†^](#t001fn004){ref-type="table-fn"}^,^[^‡^](#t001fn005){ref-type="table-fn"}   5 (35.7%)[^†^](#t001fn004){ref-type="table-fn"}
  Cardiovascular disease                                                           2 (5.6%)                 13 (32.6%)[^†^](#t001fn004){ref-type="table-fn"}    9 (45.0%)[^†^](#t001fn004){ref-type="table-fn"}                                            2 (14.3%)
  Current smoking                                                                  2 (5.6%)                 8 (18.6%)                                           5 (25.0%)                                                                                  3 (21.4%)
  BMI (kg/m^2^)                                                                    26.0 ±4.1                24.8 ±3.9                                           28.1 ±4.6[^‡^](#t001fn005){ref-type="table-fn"}                                            27.9 ±4.7[^‡^](#t001fn005){ref-type="table-fn"}
  Fluid overload (L)                                                               0.04 ±1.1                1.3 ±2.0[^†^](#t001fn004){ref-type="table-fn"}      1.2 ±1.5[^†^](#t001fn004){ref-type="table-fn"}                                             1.7 ±2.0[^†^](#t001fn004){ref-type="table-fn"}
  SBP (mmHg)                                                                       138.9 ±15.1              147.1 ±23.2[^†^](#t001fn004){ref-type="table-fn"}   156.6 ±24.6[^†^](#t001fn004){ref-type="table-fn"}                                          156.9 ±28.5[^†^](#t001fn004){ref-type="table-fn"}
  DBP (mmHg)                                                                       85.4 ±10.1               83.0 ±13.1                                          80.6 ±10.6                                                                                 87.5 ±11.2
  Renin-angiotensin-aldosterone system inhibitor use                               2 (5.6%)                 18 (41.9%)                                          10 (50.0%)                                                                                 11 (78.6%)
  Statin use                                                                       2 (5.6%)                 22 (51.2%)                                          9 (45.0%)                                                                                  10 (71.4%)

Data are presented as n (%), mean ± standard deviation, or median \[25^th^ percentile-- 75^th^ percentile\].

Abbreviations: AU, arbitrary units; BMI, body mass index; CKD5-D, chronic kidney disease stage 5 dialysis; CKD5-ND, chronic kidney disease stage 5 non-dialysis; DBP, diastolic blood pressure; eGFR~CKD-EPI~, estimated glomerular filtration rate based on the creatinine CKD-EPI equation; eGFR~residual~, estimated residual GFR based on β2-microglobulin; HD, hemodialysis; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; IL-8, interleukin 8; KTx, kidney transplantation; MMF, mycophenolate mofetil; NA, not applicable; PD, peritoneal dialysis; SAA, serum amyloid A; SBP, systolic blood pressure; sICAM-1, soluble intercellular adhesion molecule 1; sICAM-3, soluble intercellular adhesion molecule 3; sVCAM-1, soluble vascular cell adhesion molecule 1; TAC, tacrolimus; TNF-α, tumor necrosis factor alpha.

\* Available in (Controls/ CKD5-ND/ CKD5-HD/ CKD-5-PD) n = NA/ NA/ 16/ 11 for dialysis vintage, n = NA/ NA/ 13/ 11 for Kt/V, n = 36/ 42/ 20/ 14 for serum creatinine, n = 36/ 42/ NA/ NA for eGFR~CKD-EPI~, n = NA/ NA/ 15/ 10 for eGFR~residual~, n = 22/ 44/ 20/ 14 for diuresis / residual urine output (dichotomous), n = 14/ 27/ 20/ 14 for diuresis / residual urine output (continuous).

^†^ *P* value \< 0.05 vs. controls;

^‡^ *P* value \< 0.05 vs. CKD5-ND;

^¶^ *P* value \< 0.05 vs. CKD5-HD.

Unadjusted post-hoc comparisons of controls, CKD5-ND, CKD5-HD and CKD5-PD were performed with the independent Student t-test for normally distributed data, Dunn's test for non-normally distributed data and Fisher's exact test for categorical data if an ANOVA, Kruskal-Wallis test and Fisher's exact test, respectively, indicated an overall difference between groups.

Participants with CKD5-HD and CKD5-PD more often had diabetes mellitus than those with CKD5-ND. All participants with CKD5-ND and most with CKD5-HD or CKD5-PD had residual urine output. Participants with CKD5-PD were slightly younger, less often men, less often had a history of CVD, and had higher residual GFR (eGFR~residual~), slightly more fluid overload and shorter dialysis vintage than participants with CKD5-HD, although not all differences were statistically significant in this relatively small study population.

Correlations among serum biomarkers {#sec016}
-----------------------------------

In general, the strength of correlations among serum biomarkers of ED and among serum biomarkers of LGI varied. In addition, there was no strict distinction between serum biomarkers of ED and serum biomarkers of LGI in view of the degree of correlation. Further, for some serum biomarkers, correlations in the dialysis groups were in the opposite direction as compared with those in CKD5-ND and controls ([S2 Fig](#pone.0222547.s002){ref-type="supplementary-material"}).

Associations of end-stage renal disease with serum biomarkers of endothelial dysfunction and low-grade inflammation {#sec017}
-------------------------------------------------------------------------------------------------------------------

[S1 Table](#pone.0222547.s004){ref-type="supplementary-material"} and [Fig 1](#pone.0222547.g001){ref-type="fig"} shows the distributions of serum biomarkers of ED and LGI stratified by participant group.

![Boxplots of serum biomarkers of endothelial dysfunction and low-grade inflammation stratified according to participant group.\
Abbreviations: hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; IL-8, interleukin 8; NA, not applicable; SAA, serum amyloid A; sICAM-1, soluble intercellular adhesion molecule 1; sICAM-3, soluble intercellular adhesion molecule 3; sVCAM-1, soluble vascular cell adhesion molecule 1; TNF-α, tumor necrosis factor alpha. Please note that in the boxplot of IL-8 levels in controls, one extreme outlier with an IL-8 level of 2469.8 ng/L was removed to improve the clarity of the graph. ^†^ *P* value \< 0.05 vs. controls; ^‡^ *P* value \< 0.05 vs. CKD5-ND; ^¶^ *P* value \< 0.05 vs. CKD5-HD based on unadjusted linear regression analyses of natural log transformed serum biomarkers.](pone.0222547.g001){#pone.0222547.g001}

As compared with controls and after adjustment for age, sex and diabetes mellitus ([Table 2](#pone.0222547.t002){ref-type="table"}), sVCAM-1, E-selectin, thrombomodulin, hs-CRP, SAA, IL-6, and TNF-α were higher in CKD5-ND, CKD5-HD and CKD5-PD. In addition, sICAM-1 was higher in CKD5-ND and CKD5-PD, and sICAM-3 was higher in CKD5-PD only.

10.1371/journal.pone.0222547.t002

###### Associations of end-stage renal disease with serum biomarkers of endothelial dysfunction and low-grade inflammation.

![](pone.0222547.t002){#pone.0222547.t002g}

  --------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- --------------- -------------------- ---------------
                                    CKD5-ND vs. controls[\*](#t002fn005){ref-type="table-fn"}   CKD5-HD vs. controls[\*](#t002fn005){ref-type="table-fn"}   CKD5-PD vs. controls[\*](#t002fn005){ref-type="table-fn"}                                        
  **Individual serum biomarkers**   **Ratio (95%CI)**                                           ***P* value**                                               **Ratio (95%CI)**                                           ***P* value**   **Ratio (95%CI)**    ***P* value**
  sVCAM-1                           1.70 (1.52; 1.90)                                           \< 0.001                                                    1.62 (1.40; 1.88)                                           \< 0.001        2.08 (1.77; 2.44)    \< 0.001
  E-selectin                        1.34 (1.10; 1.63)                                           0.004                                                       1.30 (1.00; 1.68)                                           0.048           1.98 (1.49; 2.63)    \< 0.001
  P-selectin                        1.04 (0.87; 1.25)                                           0.631                                                       1.08 (0.85; 1.37)                                           0.534           0.93 (0.71; 1.20)    0.559
  Thrombomodulin                    4.04 (3.62; 4.52)                                           \< 0.001                                                    4.18 (3.62; 4.83)                                           \< 0.001        5.45 (4.65; 6.39)    \< 0.001
  sICAM-1                           1.19 (1.08; 1.32)                                           \< 0.001                                                    1.08 (0.95; 1.23)                                           0.252           1.26 (1.09; 1.45)    0.002
  sICAM-3                           1.14 (0.95; 1.37)                                           0.161                                                       1.12 (0.88; 1.42)                                           0.354           1.61 (1.23; 2.09)    \< 0.001
  hs-CRP                            3.14 (1.73; 5.72)                                           \< 0.001                                                    3.28 (1.49; 7.21)                                           \< 0.001        3.28 (1.38; 7.80)    \< 0.001
  SAA                               2.88 (1.61; 5.15)                                           \< 0.001                                                    3.65 (1.70; 7.84)                                           0.001           4.18 (1.80; 9.67)    0.001
  IL-6                              2.04 (1.48; 2.80)                                           \< 0.001                                                    1.88 (1.24; 2.86)                                           0.003           1.92 (1.22; 3.05)    0.006
  IL-8                              1.10 (0.78; 1.56)                                           0.579                                                       1.08 (0.69; 1.71)                                           0.728           0.78 (0.69; 1.71)    0.728
  TNF-α                             2.41 (2.13; 2.73)                                           \< 0.001                                                    2.72 (2.31; 3.20)                                           \< 0.001        2.87 (2.40; 3.43)    \< 0.001
  **Z-scores**                      **Beta (95%CI)**                                            ***P* value**                                               **Beta (95%CI)**                                            ***P* value**   **Beta (95%CI)**     ***P* value**
  Endothelial dysfunction           1.34 (1.01; 1.67)                                           \< 0.001                                                    1.20 (0.77; 1.63)                                           \< 0.001        2.00 (1.52; 2.47)    \< 0.001
  Low-grade inflammation            1.22 (0.85; 1.58)                                           \< 0.001                                                    1.18 (0.70; 1.66)                                           \< 0.001        1.48 (0.95; 2.01)    \< 0.001
                                    CKD5-HD vs. CKD5-ND[\*](#t002fn005){ref-type="table-fn"}    CKD5-PD vs. CKD5-ND[\*](#t002fn005){ref-type="table-fn"}    CKD5-PD vs. CKD5-HD[\*](#t002fn005){ref-type="table-fn"}                                         
  **Individual serum biomarkers**   **Ratio (95%CI)**                                           ***P* value**                                               **Ratio (95%CI)**                                           ***P* value**   **Ratio (95%CI)**    ***P* value**
  sVCAM-1                           0.95 (0.83; 1.09)                                           0.491                                                       1.22 (1.05; 1.42)                                           0.010           1.28 (1.08; 1.52)    0.004
  E-selectin                        0.97 (0.76; 1.23)                                           0.786                                                       1.47 (1.12; 1.93)                                           0.005           1.52 (1.13; 2.06)    0.006
  P-selectin                        1.03 (0.83; 1.29)                                           0.783                                                       0.89 (0.69; 1.14)                                           0.337           0.86 (0.65; 1.13)    0.276
  Thrombomodulin                    1.03 (0.90; 1.18)                                           0.633                                                       1.35 (1.16; 1.57)                                           \< 0.001        1.30 (1.10; 1.54)    0.002
  sICAM-1                           0.91 (0.80; 1.02)                                           0.110                                                       1.06 (0.92; 1.21)                                           0.430           1.17 (1.00; 1.36)    0.046
  sICAM-3                           0.98 (0.78; 1.23)                                           0.880                                                       1.41 (1.10; 1.81)                                           0.008           1.43 (1.08; 1.90)    0.012
  hs-CRP                            1.04 (0.50; 2.18)                                           0.909                                                       1.04 (0.46; 2.38)                                           0.920           1.00 (0.40; 2.49)    0.999
  SAA                               1.27 (0.62; 2.59)                                           0.510                                                       1.45 (0.65; 3.22)                                           0.359           1.14 (0.47; 2.77)    0.765
  IL-6                              0.92 (0.62; 1.36)                                           0.684                                                       0.94 (0.61; 1.46)                                           0.792           1.02 (0.63; 1.66)    0.928
  IL-8                              0.98 (0.64; 1.51)                                           0.937                                                       0.71 (0.44; 1.15)                                           0.158           0.72 (0.43; 1.23)    0.225
  TNF-α                             1.13 (0.97; 1.31)                                           0.124                                                       1.19 (1.00; 1.41)                                           0.047           1.06 (0.87; 1.27)    0.572
  **Z-scores**                      **Beta (95%CI)**                                            ***P* value**                                               **Beta (95%CI)**                                            ***P* value**   **Beta (95%CI)**     ***P* value**
  Endothelial dysfunction           -0.14 (-0.55; 0.26)                                         0.485                                                       0.65 (0.20; 1.11)                                           0.005           0.80 (0.30; 1.30)    0.002
  Low-grade inflammation            -0.03 (0.48; 0.42)                                          0.880                                                       0.27 (-0.24; 0.77)                                          0.293           0.30 (-0.25; 0.86)   0.283
  --------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- --------------- -------------------- ---------------

Ratios represent the ratio of (geometric mean) levels of the serum biomarkers in the respective end-stage renal disease group relative to controls, relative to individuals with chronic kidney disease stage 5 non-dialysis, chronic kidney disease stage 5 hemodialysis, and chronic kidney disease stage 5 peritoneal dialysis, respectively.

Betas represent the differences in Z-scores for endothelial dysfunction and low-grade inflammation (expressed as standard deviations) between the respective end-stage renal disease group and controls, and among the respective end-stage renal disease groups.

All analyses are adjusted for age, sex and diabetes mellitus.

Abbreviations: CKD5-HD, chronic kidney disease stage 5 hemodialysis; CKD5-ND, chronic kidney disease stage 5 non-dialysis; CKD5-PD, chronic kidney disease stage 5 peritoneal dialysis; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; IL-8, interleukin 8; SAA, serum amyloid A; sICAM-1, soluble intercellular adhesion molecule 1; sICAM-3, soluble intercellular adhesion molecule 3; sVCAM-1, soluble vascular cell adhesion molecule 1; TNF-α, tumor necrosis factor alpha.

\* Analyses based on (Controls/ CKD5-ND/ CKD5-HD/ CKD5-PD) n = 36/43/20/14.

These results of individual serum biomarkers were also reflected by higher Z-scores for ED and LGI in CKD5-ND, CKD5-HD and CKD5-PD.

As compared with CKD5-ND and after adjustment for age, sex and diabetes mellitus ([Table 2](#pone.0222547.t002){ref-type="table"}), biomarkers of ED and LGI were in general similar in CKD5-HD. In addition, as compared with both CKD5-ND and CKD5-HD, sVCAM-1, E-selectin, thrombomodulin, sICAM-3 were higher in CKD5-PD. Further, as compared with CKD5-HD, sICAM-1 was higher in CKD5-PD.

These results of individual serum biomarkers were also reflected by a higher Z-score for ED, but not LGI, in CKD5-PD as compared with CKD5-ND and CKD5-HD.

The above results were not materially changed after additional adjustment for systolic or diastolic blood pressure, use of renin-angiotensin-aldosterone system inhibitors, use of HMG-CoA inhibitors, current smoking or BMI (results not shown).

Population characteristics---Longitudinal analyses {#sec018}
--------------------------------------------------

Thirty-four participants with CKD5-ND who initiated dialysis (18 HD, 16 PD), 6 with CKD5-ND who received a kidney transplant, and 5 on chronic dialysis who received a kidney transplant were included in the longitudinal analyses ([S2 Table](#pone.0222547.s005){ref-type="supplementary-material"}; [S1 Fig](#pone.0222547.s001){ref-type="supplementary-material"}). In addition, 4 participants who initiated dialysis and later received a kidney transplant were included as kidney transplant recipients as well.

As compared with kidney transplant recipients, incident HD and PD patients were older (65.1 ±12.0 and 57.1 ±12.1 years vs. 51.6 ±12.8 years) and more often had a history of CVD (38.9% and 31.2% vs. 13.3%). In addition, incident HD patients were more often men (83.3% vs. 60.0%). Estimated GFR~CKD-EPI~ was similar and all participants had residual urine output. Incident dialysis patients on PD were younger (57.1 ±12.1 vs. 65.1 ±12.0 years) and less often men (56.2% vs. 83.3%), and had lower BMI (23.5 ±3.0 vs. 26.6 ±3.8 kg/m^2^), higher diastolic blood pressure (87.3 ±16.0 vs. 77.4 ±9.2 mmHg), and less fluid overload (0.8 ±1.4 vs. 1.9 ±2.4 L), although not all differences were statistically significant. One PD patient switched to HD during follow-up.

Courses of serum biomarkers of endothelial dysfunction and low-grade inflammation following dialysis initiation {#sec019}
---------------------------------------------------------------------------------------------------------------

Figs [2](#pone.0222547.g002){ref-type="fig"} and [3](#pone.0222547.g003){ref-type="fig"} and [S3 Table](#pone.0222547.s006){ref-type="supplementary-material"} provide data on the distributions and individual trajectories of serum biomarkers of ED and LGI in incident HD and incident PD patients from baseline up to six months after dialysis initiation.

![Boxplots and individual trajectories of serum biomarkers of endothelial dysfunction and low-grade inflammation over time in incident hemodialysis patients.\
Abbreviations: hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; IL-8, interleukin 8; NA, not applicable; SAA, serum amyloid A; sICAM-1, soluble intercellular adhesion molecule 1; sICAM-3, soluble intercellular adhesion molecule 3; sVCAM-1, soluble vascular cell adhesion molecule 1; TNF-α, tumor necrosis factor alpha. ^†^ *P* value \< 0.05 vs. baseline based on linear mixed model analyses with a random intercept.](pone.0222547.g002){#pone.0222547.g002}

![Boxplots and individual trajectories of serum biomarkers of endothelial dysfunction and low-grade inflammation over time in incident peritoneal dialysis patients.\
Abbreviations: hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; IL-8, interleukin 8; NA, not applicable; SAA, serum amyloid A; sICAM-1, soluble intercellular adhesion molecule 1; sICAM-3, soluble intercellular adhesion molecule 3; sVCAM-1, soluble vascular cell adhesion molecule 1; TNF-α, tumor necrosis factor alpha. ^†^ *P* value \< 0.05 vs. baseline based on linear mixed model analyses with a random intercept.](pone.0222547.g003){#pone.0222547.g003}

In linear mixed model analyses ([Table 3](#pone.0222547.t003){ref-type="table"}), incident HD patients showed a an increase in sVCAM-1, P-selectin and TNF-α from baseline to six months after dialysis initiation, although this change was only borderline statistically significantly for sVCAM-1. In addition, hs-CRP, SAA and IL-6 were lower after six months of follow-up.

10.1371/journal.pone.0222547.t003

###### Course of serum biomarkers of endothelial dysfunction and low-grade inflammation stratified by dialysis modality.

![](pone.0222547.t003){#pone.0222547.t003g}

                               Ratios of biomarker following dialysis initiation levels[\*](#t003fn003){ref-type="table-fn"}              
  ----------------------- ---- ----------------------------------------------------------------------------------------------- ---------- -------
  sVCAM-1 (μg/L)          HD   1.06 (0.99; 1.14)                                                                               0.090      0.598
                          PD   1.09 (1.01; 1.18)                                                                               0.023      
  E-selectin (μg/L)       HD   1.00 (0.88; 1.14)                                                                               0.983      0.509
                          PD   1.07 (0.93; 1.23)                                                                               0.355      
  P-selectin (μg/L)       HD   1.24 (1.10; 1.38)                                                                               \< 0.001   0.015
                          PD   1.00 (0.89; 1.13)                                                                               0.938      
  Thrombomodulin (μg/L)   HD   1.06 (0.97; 1.15)                                                                               0.224      0.335
                          PD   1.12 (1.02; 1.23)                                                                               0.017      
  sICAM-1 (μg/L)          HD   0.98 (0.90; 1.07)                                                                               0.720      0.036
                          PD   1.13 (1.03; 1.24)                                                                               0.012      
  sICAM-3 (μg/L)          HD   1.06 (0.98; 1.14)                                                                               0.152      0.022
                          PD   1.20 (1.11; 1.30)                                                                               \< 0.001   
  hs-CRP (mg/L)           HD   0.54 (0.36; 0.81)                                                                               0.004      0.015
                          PD   1.14 (0.74; 1.74)                                                                               0.543      
  SAA (mg/L)              HD   0.50 (0.30; 0.82)                                                                               0.008      0.057
                          PD   1.01 (0.59; 1.73)                                                                               0.961      
  IL-6 (ng/L)             HD   0.82 (0.65; 1.04)                                                                               0.094      0.052
                          PD   1.15 (0.90; 1.46)                                                                               0.261      
  IL-8 (ng/L)             HD   1.02 (0.81; 1.27)                                                                               0.887      0.462
                          PD   0.90 (0.71; 1.14)                                                                               0.381      
  TNF-α (ng/L)            HD   1.27 (1.08; 1.49)                                                                               \< 0.001   0.306
                          PD   1.13 (0.95; 1.33)                                                                               0.164      

Ratios represent the ratio of (geometric mean) levels of the biomarkers at the respective time point after dialysis initiation relative to baseline levels based on a linear mixed model containing the respective serum biomarkers, categorical time, serum biomarker\*categorical time, and a random intercept.

Abbreviations: hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; IL-8, interleukin 8; NA, not applicable; SAA, serum amyloid A; sICAM-1, soluble intercellular adhesion molecule 1; sICAM-3, soluble intercellular adhesion molecule 3; sVCAM-1, soluble vascular cell adhesion molecule 1; TNF-α, tumor necrosis factor alpha.

\* Analyses based on (incident hemodialysis/ incident peritoneal dialysis) n = 18/16.

\*\* *P* value for the interaction term between categorical time and dialysis modality.

In linear mixed model analyses ([Table 3](#pone.0222547.t003){ref-type="table"}), incident PD patients showed a statistically significant increase in sVCAM-1, thrombomodulin, sICAM-1 and sICAM-3 from baseline to six months after dialysis initiation.

In these analyses, statistically significant interaction terms suggested that the courses of P-selectin, sICAM-1, sICAM-3, hs-CRP, SAA and IL-6 were different between incident HD and incident PD patients (*P*~interaction~ \< 0.10).

Courses of serum biomarkers of endothelial dysfunction and low-grade inflammation following kidney transplantation {#sec020}
------------------------------------------------------------------------------------------------------------------

[Fig 4](#pone.0222547.g004){ref-type="fig"} and [S4 Table](#pone.0222547.s007){ref-type="supplementary-material"} provide data on the distributions and individual trajectories of serum biomarkers of ED and LGI in kidney transplant recipients from baseline up to six months post-transplantation.

![Boxplots and individual trajectories of serum biomarkers of endothelial dysfunction and low-grade inflammation over time in kidney transplant recipients.\
Abbreviations: hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; IL-8, interleukin 8; NA, not applicable; SAA, serum amyloid A; sICAM-1, soluble intercellular adhesion molecule 1; sICAM-3, soluble intercellular adhesion molecule 3; sVCAM-1, soluble vascular cell adhesion molecule 1; TNF-α, tumor necrosis factor alpha. ^†^ *P* value \< 0.05 vs. baseline based on linear mixed model analyses with a random intercept.](pone.0222547.g004){#pone.0222547.g004}

In linear mixed model analyses ([Table 4](#pone.0222547.t004){ref-type="table"}), kidney transplant recipients showed a statistically significant reduction in sVCAM-1, thrombomodulin, sICAM-3, and TNF-α at three months post-transplantation, which was still present after six months of follow-up. In addition, E-selectin, hs-CRP, SAA and IL-6 were lower at three and six months post-transplantation with similar or even larger magnitudes of effect (*i*.*e*., ratios), albeit not statistically significantly and with wide 95% confidence intervals.

10.1371/journal.pone.0222547.t004

###### Courses of serum biomarkers of endothelial dysfunction and low-grade inflammation following kidney transplantation.

![](pone.0222547.t004){#pone.0222547.t004g}

  Kidney transplant recipients   Ratios of biomarkers following kidney transplantation[\*](#t004fn003){ref-type="table-fn"}                                  
  ------------------------------ -------------------------------------------------------------------------------------------- ---------- ------------------- ----------
  sVCAM-1 (μg/L)                 0.78 (0.68; 0.90)                                                                            0.001      0.76 (0.66; 0.88)   \< 0.001
  E-selectin (μg/L)              0.83 (0.67; 1.02)                                                                            0.075      0.85 (0.69; 1.05)   0.128
  P-selectin (μg/L)              0.99 (0.81; 1.22)                                                                            0.941      1.20 (0.98; 1.47)   0.077
  Thrombomodulin (μg/L)          0.38 (0.32; 0.44)                                                                            \< 0.001   0.39 (0.33; 0.45)   \< 0.001
  sICAM-1 (μg/L)                 0.99 (0.85; 1.17)                                                                            0.943      0.94 (0.80; 1.10)   0.441
  sICAM-3 (μg/L)                 0.73 (0.63; 0.84)                                                                            \< 0.001   0.78 (0.68; 0.91)   \< 0.001
  hs-CRP (mg/L)                  0.44 (0.18; 1.11)                                                                            0.079      0.52 (0.21; 1.29)   0.152
  SAA (mg/L)                     0.76 (0.29; 1.99)                                                                            0.565      0.64 (0.24; 1.66)   0.342
  IL-6 (ng/L)                    0.67 (0.40; 1.11)                                                                            0.112      0.67 (0.40; 1.11)   0.112
  IL-8 (ng/L)                    0.91 (0.51; 1.61)                                                                            0.732      1.30 (0.73; 2.31)   0.357
  TNF-α (ng/L)                   0.57 (0.44; 0.73)                                                                            \< 0.001   0.54 (0.42; 0.69)   \< 0.001

Ratios represent the ratio of (geometric mean) levels of the biomarkers at the respective time point after kidney transplantation relative to baseline levels based on a linear mixed model containing categorical time and a random intercept.

Abbreviations: hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; IL-8, interleukin 8; NA, not applicable; SAA, serum amyloid A; sICAM-1, soluble intercellular adhesion molecule 1; sICAM-3, soluble intercellular adhesion molecule 3; sVCAM-1, soluble vascular cell adhesion molecule 1; TNF-α, tumor necrosis factor alpha.

\* Analyses based on n = 15.

Additional analyses {#sec021}
-------------------

First, when we excluded outliers (*i*.*e*., defined as participants with standardized residuals \< 2 or \> 2 SD) in the cross-sectional linear regression analyses, results were largely similar ([S5 Table](#pone.0222547.s008){ref-type="supplementary-material"}). Most notable dissimilarities after exclusion of outliers were a smaller difference between CKD5-HD and CKD5-PD for E-selectin; more pronounced differences in SAA between CKD5-HD/CKD5-PD and CKD5-ND; and more pronounced differences in Z-score for LGI between CKD5-PD and CKD5-ND/CKD5-HD.

Second, when we excluded outliers in analyses for the courses of serum biomarkers following dialysis initiation ([S6 Table](#pone.0222547.s009){ref-type="supplementary-material"}) and kidney transplantation ([S7 Table](#pone.0222547.s010){ref-type="supplementary-material"}), results were in general similar or somewhat more pronounced.

Third, results of cross-sectional analyses were similar after exclusion of participants with a history of KTx (results not shown).

Fourth, results of longitudinal analyses were similar for incident HD and PD patients after exclusion of participants with a history of KTx (results not shown). In addition, for kidney transplant recipients, results were largely similar, except for the decline in hs-CRP, SAA and IL-6 which was more pronounced after exclusion of participants with prior KTx ([S8 Table](#pone.0222547.s011){ref-type="supplementary-material"}).

Fifth, cross-sectional difference in sICAM-3 and the Z-score for ED between CKD5-HD and CKD5-PD were attenuated by \~45% and \~15%, respectively, after additional adjustment for dialysis vintage. In contrast, results were similar after additional adjustment for eGFR~residual~, residual urine output and fluid overload (results not shown).

Sixth, additional adjustment for eGFR~residual~ in linear mixed model analyses attenuated the courses of sVCAM-1 in incident HD and thrombomodulin in incident PD, but did not explain the courses in the other serum biomarkers ([S9 Table](#pone.0222547.s012){ref-type="supplementary-material"}).

Discussion {#sec022}
==========

This study on ED and LGI on individuals transitioning from untreated ESRD to renal replacement therapy had four main findings. First, participants with ESRD had higher levels of most serum biomarkers of ED and LGI than controls. Second, in participants with CKD5-HD, levels of serum biomarkers of ED and LGI were largely similar to those in CKD5-ND. In contrast, participants with CKD5-PD had higher levels of biomarkers of ED than participants with CKD5-ND and CKD5-HD. Third, incident PD patients showed an increase in several serum biomarkers of ED as well, but no convincing change in serum biomarkers of LGI. In contrast, results for incident HD patients were mixed, with an increase in some serum biomarkers of ED and LGI, but a decrease in other biomarkers of LGI. Fourth, following kidney transplantation levels of several serum biomarkers of ED and LGI were lower at three months post-transplantation and remained stable at three months thereafter.

Higher levels of multiple serum biomarkers of ED and LGI in participants with ESRD fits previous literature that characterizes ESRD as a state of ED and LGI\[[@pone.0222547.ref026],[@pone.0222547.ref027]\]. In addition, these results indicate that multiple endothelial functions (including regulation of leukocyte adhesion and hemostasis) and inflammatory pathways are affected.

Differences were most remarkable for sVCAM-1, thrombomodulin and TNF-α. In this regard, VCAM-1 is a cell adhesion molecule, which is upregulated by cytokines, including TNF-α\[[@pone.0222547.ref028]\]. Increased levels of TNF-α may reflect activation of the TNF-α system of peripheral blood monocytes, which could be involved in the immunoincompetence of ESRD patients as well\[[@pone.0222547.ref029]\]. In addition, increased thrombomodulin levels may indicate ED and/or a hypercoagulable state in ESRD\[[@pone.0222547.ref030]\].

The causal mechanisms of ED and LGI in ESRD are likely multifactorial and may include exposure to traditional CVD risk factors, oxidative stress, fluid and sodium overload, gut dysbiosis, accumulation of uremic toxins\[[@pone.0222547.ref014],[@pone.0222547.ref026],[@pone.0222547.ref031]\], and turbulent flow\[[@pone.0222547.ref032]\] due to the hyperdynamic circulation after arteriovenous shunt creation\[[@pone.0222547.ref033]\]. In addition, ED and LGI may be interrelated\[[@pone.0222547.ref034]\] as illustrated by the correlation matrix.

Dialysis initiation could either attenuate or augment ED and LGI, which may depend on the relative contributions of improved clearance of uremic toxins and bioincompatibility of the dialysis membrane\[[@pone.0222547.ref035]--[@pone.0222547.ref037]\].

In this study, both CKD5-PD and incident PD showed an increase in serum biomarkers of ED but not convincingly of serum biomarkers of LGI. In addition, several serum biomarkers of ED were higher in CKD5-PD than in CKD5-HD.

Increases in serum biomarkers of ED following PD initiation have been described previously and hypothesized explanations include alterations in fluid status, mechanical stress of intraperitoneal capillaries and toxicity of absorbed constituents of PD fluid\[[@pone.0222547.ref015]\]. In this study, cross-sectional differences between CKD5-HD and CKD-PD were not explained by fluid overload. However, the comparison of HD and PD should be interpreted with caution as the subgroups were small.

For HD it is less clear whether the observed changes reflect effects of dialysis treatment on selected endothelial functions (*i*.*e*. cellular adhesion) and pathways of LGI, or are the result of the play of chance, as results of the cross-sectional and longitudinal analyses were incongruent. Survivorship bias in prevalent dialysis patients with lower levels of sVCAM-1, P-selectin and TNF-α could be a potential explanation in favor of the results of the longitudinal analyses. In addition, their role as acute phase proteins may confound the courses of hs-CRP, SAA and IL-6.

Kidney transplantation was followed by a reduction in several serum biomarkers of ED and LGI, which was most convincingly shown for sVCAM-1, thrombomodulin, sICAM-3 and TNF-α. The decrease in serum biomarkers of ED agrees with and expands the results of a previous study that assessed ED with sVCAM-1 only\[[@pone.0222547.ref017]\]. Similarly, the decrease in serum biomarkers of LGI agrees with previous studies on this topic\[[@pone.0222547.ref018],[@pone.0222547.ref019]\].

Kidney transplantation may improve ED and LGI by reversing the uremic state that is described above. In this regard, this study indicated that a major part of the benefit of kidney transplantation on ED and LGI is already reached in the first three months post-transplantation. Given their molecular weight, improved renal clearance does not account for the reduction of serum biomarkers of ED but may (partly) explain the reduction of TNF-α\[[@pone.0222547.ref021]\]. In addition, the role of the immunosuppressive regimen is complex as individual immunosuppressive medications may have opposite effects on ED and LGI. For example, corticosteroids reduce LGI\[[@pone.0222547.ref038]\] and calcineurin inhibitors induce ED\[[@pone.0222547.ref039]\], possibly tempering the benefits of kidney transplantation.

In contrast with previous studies, this study observed no statistically significant difference in hs-CRP and IL-6 in the main analyses. This may be explained by a lack of statistical power and high variability as median levels of both serum biomarkers were numerically lower at end of follow-up. In addition, additional analyses suggested that baseline immunosuppressive use in participants with a prior KTx may have confounded results. However, these results should be interpreted with caution given the small sample size. Further, in the present study, levels of hs-CRP and IL-6 were lower as compared with previous studies\[[@pone.0222547.ref018],[@pone.0222547.ref019]\]. This may indicate a more favourable prognosis of participants of the present study, which may be related to the higher proportion of pre-emptive kidney transplantations and consequently less dialysis-induced inflammation\[[@pone.0222547.ref040],[@pone.0222547.ref041]\].

Strengths of this study were the assessment of multiple serum biomarkers of ED and LGI, and a design that combined a cross-sectional comparison of CKD5-ND, CKD5-HD, CKD5-PD and controls with follow-up data in incident patients on renal replacement therapy. This allowed examining ED and LGI in uremia *per se* as well as the additional short-term consequences of renal replacement therapy. In addition, the use of composite scores on top of an analysis of individual serum biomarkers improved statistical power and reduced biological and analytical variability in the cross-sectional analyses.

This study also had some limitations. First, statistical power was limited, in particular for the comparison of HD and PD, and for the follow-up of kidney transplant recipients. In addition, the limited number of kidney transplant recipients precluded further stratification, for example to compare participants with preemptive and non-preemptive kidney transplantation. Second, the follow-up time was relatively short. However, this study specifically focused on the transition phase from CKD5-ND to CKD5-D and from CKD5-ND to kidney transplant recipient, instead of the long-term course of ED and LGI. In addition, with regard to kidney transplantation, kidney function has stabilized at this point of time, whereas the effects of surgery are very likely to have been subdued. Third, the distribution of ESRD causes, with varying prognosis, in this study may hamper comparisons between CKD5-ND and CKD5-D patients, and may limit generalizability. For example, the prevalence of polycystic kidney disease was high, whereas that of diabetic nephropathy was low. Fourth, incomparability of characteristics of incident dialysis patients and kidney transplant recipients, which may be related to eligibility for kidney transplantation and, thus, selection bias, hampers a direct comparison between both renal replacement therapies. Fifth, in this observational study, the immunosuppressive regimen was protocolized but not fully standardized, which may hamper the interpretation of results in kidney transplant recipients. Sixth, this study cannot examine whether ED and LGI explain the increased CVD risk in uremia, after dialysis initiation and after kidney transplantation, as data on CVD events were lacking. Nevertheless, the results of this study suggest that it is worthwhile to address this question in a study with data on clinical outcome.

In conclusion, levels of serum biomarkers of ED and LGI were higher in ESRD as compared with controls. In addition, PD initiation and, less convincingly, HD initiation may increase levels of selected serum biomarkers of ED and LGI on top of uremia *per se*. However, the finding that this was not readily apparent for all examined serum biomarkers fits the hypothesis that ED and LGI for a large part already develop in earlier CKD stages. In contrast to dialysis, kidney transplantation led to a marked improvement of several serum biomarkers of ED and LGI.
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2\. Has the statistical analysis been performed appropriately and rigorously?
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Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript is of interest providing some interesting data on the evolution of biomarkers of endothelial function and inflammation, but many concerns are present.

General comments: The manuscript is very difficult to read with a tendency to be confused. Statistical analysis must be reviewed by a specialist.

The abstract must be reviewed. The methods and results are not clear and the conclusion I is not really conclusive. Word (completely between the brackets is not a good idea in a scientific paper.

Ref 3 is of no interest and must be removed.

In methods part, the timing of blood samples collection must be more precise. First the vintage of collection must be given for all the patients. Second, the timing of collection regarding the dialysis séance must be precise, first, second or third dialysis of the week. Third, for the biomarkers, how the sample were conserved? All the measurements were done at the same time? Did the authors have data on the effects of blood conservation on the concentration of the biomarkers?

For others biological value the technique of dosage must be provide.

Finally, the kidney transplantation protocol is very different with three patient included in a randomized trial. I think these patients must be excluded. The values, especially for inflammation markers are very difficult to interpret when one a small sample of patients (15) you have 3 with monotherapy with tacrolimus, 5 with tacro and MMF and 7 with Tacro MMF and corticoids. It is not clear for me for patients with everolimus if they are still with everolimus or not.

Pour les dilyser penser à discuter les différentes membranes.

In results,

In table 1, the authors must separate HD and PD patients. In controls and CKD5-ND it is not residual urine outpout but diuresis. In this table, in the 18% of patient with CKD have a history of Ktx, did they have an immunosuppressive drugs? This must be stated and clear in the characteristics of the patients. It is very different to study endothelial dysfunction to have or not IS drugs.

Important clinical data are missing: tobacco, alcool, lipids concentration, calcium phosphore bicarbonate potassium, hb etc. Medications used, mainly immunosuppressive drugs and corticoids, antihypertensive drugs, HMG CoA inhibitors, anticoagulants, aspirin etc. All this drugs could play an important role on endothelial function and inflammation.

For the table 2, supplementary analysis separating HD and PD must be done. Adjustment with blood pressure could be of interest mainly regarding endothelial dysfunction.

For the longitudinal analysis we must have separation of PD and HD patients. In addition, in my opinion for dialysis patient regarding the boxplot there is no real differences in all the biomarkers, the test used for statistical significance must be provide explicitly in the results. More interesting than a box blot the authors must provide individual courses of the biomarkers separating HD and PD.

We must have comparisons with other biological values, like calcium phosphore, bicarbonate urea, creatininemia etc.

For transplantation patients same remarks regarding the representation of data. It could be of interest to indicate the course of values for the 4 patients undergoing dialysis then transplantation the data.

The additional analysis section is a non sense. All this analysis must be included with main analysis or not discusses. The patients with cyst infection must be definitively excluded.

The discussion will be analyzed after the modification asked for the methods and results.

Reviewer \#2: In the present study, the authors compared biomarkers of endothelium dysfunction and low-grade inflammation in controls and in different groups of CKD patients. They show that most biomarkers are higher in CKD patients than in controls, higher in dialysis patients than in non-dialyzed patients and decline after kidney transplantation. Higher levels of serum biomarkers of ED and LGI in CKD patients have been previously shown in the literature. In addition, the data on serum biomarkers after kidney transplantation do not provide new informations and only confirm previous studies.

1\) The design of the study is complex. It mixes the data of three separate observational studies, but the number of subjects per group is quite low. The characteristics of CKD5-ND and CKD5-D patients are different in terms of origin of end stage renal disease, and presence of diabetes mellitus.

2\) Patients on PD are different from patients on HD (younger, less CVD history, higher residual GFR...), and additional analysis demonstrated differences in biomarkers in these two groups of patients. Therefore,the authors should not include these patients in the same CKD5D group.

3\) The choice of statistical analyses is not clear. Why do the authors compare the data of biomarkers between groups with linear regression analysis and not with tests for group comparison like ANOVA or Mann Whitney? In addition, why do the authors use a natural log transformation to perform statistical test on the levels of serum biomarkers? How is the distribution of the data (normal or not)?

4\) Identical data are presented several times, in different figures/tables. For example, Figure 2 and Table 3 provides the same informations, data in Table 3 are also in S1 Table etc...

5\) For a better understanding, the authors should add the symbols of p values on figures and tables. In particular, the p values between CKD5-ND and CKD5D should be mentioned in Table 1.

6\) In table 3, an entire column is NA, please remove the column. In S1 Table, dialysis vintage and KT/V are NA, please remove the lines.

Reviewer \#3: Manuscript is well written. Only minor suggestions to improve the manuscript.

Please try to avoid the use of () in the descriptive sentences in academic writing "This risk is not (completely) mitigated by renal replacement therapy"

"Only data of their first study was analyzed" "of" should be "from"

Also, I suggest the investigators to may improve the introduction/discussion by going over very nice review on this topic PMID: 30607032 Nat Rev Nephrol. 2019 Feb;15(2):87-108. doi: 10.1038/s41581-018-0098-z
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Dear editor, dear reviewers,

Thank you for providing us an opportunity to revise our manuscript. We thank the editor and the reviewers for their thoughtful comments and suggestions which have helped us to improve our manuscript. For your convenience, please find below, in bold, our point-by-point rebuttal. All changes made in the manuscript are highlighted with 'tracked changes'. The page numbers of the manuscript are used below to indicate where the changes have been made.

On behalf of all authors,

Yours sincerely,

April van Gennip, MD Remy Martens, MD, PhD

 

Response to the Reviewer \#1

The manuscript is of interest providing some interesting data on the evolution of biomarkers of endothelial function and inflammation, but many concerns are present.

General comments: The manuscript is very difficult to read with a tendency to be confused. Statistical analysis must be reviewed by a specialist.

We thank the reviewer for the time spend to review the manuscript.

1\) The abstract must be reviewed. The methods and results are not clear and the conclusion I is not really conclusive.

We have reviewed and updated the abstracts within the constraints of the word limits (page 2-3, lines 37-67):

"Introduction: End-stage renal disease (ESRD) strongly associates with cardiovascular disease (CVD) risk. This risk is not completely mitigated by renal replacement therapy. Endothelial dysfunction (ED) and low-grade inflammation (LGI) may contribute to the increased CVD risk. However, data on serum biomarkers of ED and LGI during the transition to renal replacement therapy (dialysis and kidney transplantation) are scarce.

Methods: We compared serum biomarkers of ED and LGI between 36 controls, 43 participants with chronic kidney disease (CKD) stage 5 non-dialysis (CKD5-ND), 20 participants with CKD stage 5 hemodialysis (CKD5-HD) and 14 participants with CKD stage 5 peritoneal dialysis (CKD5-PD). Further, in 34 and 15 participants repeated measurements were available during the first six months following dialysis initiation and kidney transplantation, respectively. Serum biomarkers of ED (sVCAM-1, E-selectin, P-selectin, thrombomodulin, sICAM-1, sICAM-3) and LGI (hs-CRP, SAA, IL-6, IL-8, TNF-α) were measured with a single- or multiplex array detection system based on electro-chemiluminescence technology.

Results: In linear regression analyses adjusted for potential confounders, participants with ESRD had higher levels of most serum biomarkers of ED and LGI than controls. In addition, in CKD5-HD levels of serum biomarkers of ED and LGI were largely similar to those in CKD5-ND. In contrast, in CKD5-PD levels of biomarkers of ED were higher than in CKD5-ND and CKD5-HD. Similarly, in linear mixed model analyses sVCAM-1, thrombomodulin, sICAM-1 and sICAM-3 increased after PD initiation. In contrast, incident HD patients showed an increase in sVCAM-1, P-selectin and TNF-α, but a decline of hs-CRP, SAA and IL-6. Further, following kidney transplantation sVCAM-1, thrombomodulin, sICAM-3 and TNF-α were lower at three months post-transplantation and remained stable in the three months thereafter.

Conclusions: Levels of serum biomarkers of ED and LGI were higher in ESRD as compared with controls. In addition, PD initiation and, less convincingly, HD initiation may increase levels of selected serum biomarkers of ED and LGI on top of uremia per se. In contrast to dialysis, several serum biomarkers of ED and LGI markedly declined following kidney transplantation."

2\) Word (completely between the brackets is not a good idea in a scientific paper.

We have removed the brackets as requested. Abstract (page 2, lines 39): "This risk is not (completely) mitigated by renal replacement therapy."

3\) Ref 3 is of no interest and must be removed.

We agree. This reference was inserted erroneously and we have now removed this reference.

4\) In methods part, the timing of blood samples collection must be more precise. First the vintage of collection must be given for all the patients.

It is not entirely clear what the reviewer means with 'vintage of collection'. All samples were collected during the period the study was conducted. This is described in the methods section in the paragraph study population and design. The studies included were conducted between February 2012 and July 2017, between October 2013 and January 2018, and between June 2012 and December 2017, respectively.

5\) Second, the timing of collection regarding the dialysis séance must be precise, first, second or third dialysis of the week.

In the group of prevalent dialysis patients samples were collected prior to each patients' mid-week dialysis session. In the group of incident dialysis patients the timing of blood sampling relative to the dialysis session was not standardized (i.e., either the first, second or third dialysis of the week). The same held true for kidney transplant patients who were on dialysis prior to KTx.

We have added this information to the Methods section (page 9, lines 194-198): "In participants on HD, study measurements and blood sampling were performed prior to one of their dialysis sessions (the midweek session for prevalent HD patients; either the first, second or third session for incident HD patients and for non-preemptively transplanted patients prior to KTx)."

6\) Third, for the biomarkers, how the sample were conserved? All the measurements were done at the same time? Did the authors have data on the effects of blood conservation on the concentration of the biomarkers?

Blood was collected in sterile 5 ml BD vacutainer SST II Advance tubes. After centrifugation, serum was aspirated and stored at -80°C until analysis. Before analysis, serum samples where thawed and mixed thoroughly.

We have added this information to the Methods (page 8, lines 156-158):" Blood was collected in sterile 5 ml BD vacutainer SST II Advance tubes. After centrifugation, serum was aspirated and stored at -80°C until analysis. Before analysis, serum samples where thawed and mixed thoroughly."

All measurements were done at the same time. Biomarkers were analyzed with 6 multiplex assays. Per assay, analyses were performed within the same batch to avoid batch effects. In addition, combining the analyses of two assays reduced the number of freeze-thaw cycles to three in total.

Unfortunately, data on long-term stability of the serum biomarkers are lacking, except for hs-CRP, which is stable up to 11 years if stored at -80°C \[1\].

7\) For others biological value the technique of dosage must be provide.

It is not clear to us what the reviewer means with 'technique of dosage'.

8\) Finally, the kidney transplantation protocol is very different with three patient included in a randomized trial. I think these patients must be excluded.

All patients received standard protocol patient care during the kidney transplant period. The only difference is the use of different immunosuppressive protocols. However, the immunosuppressive medication as described in the manuscript and used in the RCT (TRANSFORM) and the observational study are already part of standard patient care. Therefore, we chose to include these patients into the analyses since our study has an observational nature and as such therapy cannot be fully standardized.

9\) The values, especially for inflammation markers are very difficult to interpret when one a small sample of patients (15) you have 3 with monotherapy with tacrolimus, 5 with tacro and MMF and 7 with Tacro MMF and corticoids. It is not clear for me for patients with everolimus if they are still with everolimus or not.

The immunosuppressive regimen, albeit protocolized, is tailored towards the individual patient's clinical response, leading to some variation in immunosuppressive medication. This is inherent to clinical practice and the observational nature of this study.

However, we have mentioned this as a study limitation in the Discussion (page 32, lines 544-546): "Fifth, in this observational study, the immunosuppressive regimen was protocolized but not fully standardized, which may hamper the interpretation of results in kidney transplant recipients.

Two patients started with everolimus. One patient was lossed-to-follow-up, the other patient used everolimus throughout the entire study period. Which is now stated more clearly in the S1 methods: "Three patients included in this study were simultaneously enrolled in a different study (TRANSFORM) (NCT01950819). Two of these three patients were randomized to receive tacrolimus, everolimus and prednisolone as triple therapy from time of kidney transplant. One of these two patients withdrew informed consent for further follow-up in our study in the first week after kidney transplantation for personal reasons. The other received everolimus throughout the entire study period. The third patient was randomized to receive tacrolimus (prograft), MMF and prednisolone as triple therapy from time of kidney transplant. This patient switched to the local immunosuppressive protocol of our centre after the 6 month follow up visit."

10\) Pour les dilyser penser à discuter les différentes membranes.

It is not entirely clear what the reviewer means with this. An overview of the dialysis membranes used for the patients in this study is provided in S1 Methods (paragraph on dialysis therapy modalities).

11\) In results, In table 1, the authors must separate HD and PD patients. In controls and CKD5-ND it is not residual urine outpout but diuresis.

Thank you for noticing. We have changed 'residual urine output' into 'diuresis/ residual urine output' in Table 1 and S1 Table. In addition, we now present characteristics in Table 1 stratified according to controls, CKD5-ND, CKD5-HD and CKD5-PD. Similarly, we now present characteristics in S2 Table stratified according to incident HD, incident PD and kidney transplant recipients.

The description of the cross-sectional population characteristics in the Results (page 13, lines 257-266) has been adapted as well: "Thirty-six controls, 43 participants with CKD5-ND, 20 participants with CKD5-HD and 14 participants with CKD5-PD comprised the cross-sectional study population (Table 1; flowchart in S1 Fig). In general, participants with CKD5-ND, CKD5-HD and CKD5-PD were more often men and had a worse CVD risk profile than controls.

Participants with CKD5-HD and CKD5-D more often had diabetes mellitus than those with CKD5-ND. All participants with CKD5-ND and most with CKD5-D had residual urine output. Participants with CKD5-PD slightly younger, less often men, less often had a history of CVD, and had higher residual GFR (eGFRresidual), slightly more fluid overload and shorter dialysis vintage than participants with CKD5-HD, although not all differences were statistically significant in this relatively small study population."

Similarly for the description of the longitudinal population characteristics (page 20, lines 334-348): "As compared with kidney transplant recipients, incident HD and PD patients were older (65.1 ±12.0 and 57.1 ±12.1 years vs. 51.6 ±12.8 years) and more often had a history of CVD (38.9% and 31.2% vs. 13.3%). In addition, incident HD patients were more often men (83.3% vs. 60.0%). Estimated GFRCKD-EPI was similar and all participants had residual urine output. Incident dialysis patients on PD were younger (57.1 ±12.1 vs. 65.1 ±12.0 years) and less often men (56.2% vs. 83.3%), and had lower BMI (23.5 ±3.0 vs. 26.6 ±3.8 kg/m2), higher diastolic blood pressure (87.3 ±16.0 vs. 77.4 ±9.2 mmHg), and less fluid overload (0.8 ±1.4 vs. 1.9 ±2.4 L), although not all differences were statistically significant. One PD patient switched to HD during follow-up."

12\) In this table, in the 18% of patient with CKD have a history of Ktx, did they have an immunosuppressive drugs? This must be stated and clear in the characteristics of the patients. It is very different to study endothelial dysfunction to have or not IS drugs.

We agree that this information is relevant. Therefore, we have added data on immunosuppressive medication use in participants with a history of KTx in both cross-sectional and longitudinal analyses, where available, in Table and S2 Table. In addition, we have added more detailed information to S1 Methods.

S1 Methods:

"For the 14 participants who were included in the cross-sectional analyses and had a history of kidney transplantation, data on their immunosuppressive regimen were retrospectively collected from the electronic patient health record. Of the 8 participants with CKD5-ND and a history of kidney transplantation, 7 participants were on immunosuppressive therapy of whom the therapeutic regimen could be retrieved for 6 participants: 1 prednisolone monotherapy, 4 TAC monotherapy, 1 either TAC or MMF monotherapy (not entirely clear from the health record). Of the 3 participants with CKD5-HD and a history of kidney transplantation, 1 was on TAC monotherapy, 1 on MMF monotherapy and 1 did not use immunosuppressive therapy. Similarly, of the 3 participants with CKD5-PD and a history of kidney transplantation, 1 was one TAC monotherapy, 1 on MMF monotherapy and 1 did not use immunosuppressive therapy.

All incident HD patients with a history of kidney transplantation were on immunosuppressive medication: 2 TAC monotherapy from baseline throughout follow-up, 1 either TAC or MMF monotherapy (not entirely clear from the health record) from baseline up to and including the six month follow-up measurement, and for 1 of these participants the exact immunosuppressive regimen could not be retrieved.

Similarly, all incident PD patients with a history of kidney transplantation were on immunosuppressive medication: 1 prednisolone from baseline throughout follow-up and 1 TAC monotherapy from baseline up to and including the six months follow-up measurement.

All kidney transplant recipients with a history of kidney transplantation were on immunosuppressive therapy: 1 TAC monotherapy and 2 MMF monotherapy."

Further, we have performed sensitivity analyses excluding participants with prior KTx to explore confounding effects of immunosuppressive use and the presence of a KTx transplant. For cross-sectional analyses, results were similar. In addition, for longitudinal analyses, results were similar for incident HD and PD patients. Further, for kidney transplant recipients, results were largely similar, except for the decline in hs-CRP, SAA and IL-6, which was more pronounced.

We have reported these results as follows in the additional analyses section of the Results (page 27, lines 432-433):

"Third, results of cross-sectional analyses were similar after exclusion of participants with a history of KTx (results not shown).

Fourth, results of longitudinal analyses were similar for incident HD and PD patients after exclusion of participants with a history of KTx (results not shown). In addition, for kidney transplant recipients, results were largely similar, except for the decline in hs-CRP, SAA and IL-6 which was more pronounced after exclusion of participants with prior KTx (S8 Table)."

13\) Important clinical data are missing: tobacco, alcool, lipids concentration, calcium phosphore bicarbonate potassium, hb etc. Medications used, mainly immunosuppressive drugs and corticoids, antihypertensive drugs, HMG CoA inhibitors, anticoagulants, aspirin etc. All this drugs could play an important role on endothelial function and inflammation.

We agree with the reviewer that addition of these data would improve the manuscript. Therefore, we have added smoking status, use of renin-angiotensin-aldosterone system inhibitors and HMG CoA inhibitors to Table 1 and S1 Table. The use of immunosuppressive medication is already described in detail for kidney transplant recipients in S1 Methods. Unfortunately, data on the suggested laboratory values, which may provide explanatory information for the associations reported, as well as data on anticoagulant and aspirin use have not been collected for the present study.

Methods (page 9, lines 184-185): "Current smoking was based on self-report."

In addition, in line with the comment, we explored whether additional adjustment for systolic blood pressure, diastolic blood pressure, use of renin-angiotensin-aldosterone system inhibitors, use of HMG CoA inhibitors, current smoking and bmi would change results: results were similar.

Results (page 16, lines 307-309): "The above results were not materially changed after additional adjustment for systolic or diastolic blood pressure, use of renin-angiotensin-aldosterone system inhibitors, use of HMG-CoA inhibitors, current smoking or BMI (results not shown). "

14\) For the table 2, supplementary analysis separating HD and PD must be done. Adjustment with blood pressure could be of interest mainly regarding endothelial dysfunction.

We now present the analyses in Table 2 stratified for CKD5-HD and CKD5-PD.

Accordingly, the Results section (page 16, lines 292-306) has been adapted as well:

"Table S1 and Figure 1 shows the distributions of serum biomarkers of ED and LGI stratified by participant group.

As compared with controls and after adjustment for age, sex and diabetes mellitus (Table 2), sVCAM-1, E-selectin, thrombomodulin, hs-CRP, SAA, IL-6, and TNF-α were higher in CKD5-ND, CKD5-HD and CKD5-PD. In addition, sICAM-1 was higher in CKD5-ND and CKD5-PD, and sICAM-3 was higher in CKD5-PD only.

These results of individual serum biomarkers were also reflected by higher Z-scores for ED and LGI in CKD5-ND, CKD5-HD and CKD5-PD.

As compared with CKD5-ND and after adjustment for age, sex and diabetes mellitus (Table 2), biomarkers of ED and LGI were in general similar in CKD5-HD. In addition, as compared with both CKD5-ND and CKD5-HD, sVCAM-1, E-selectin, thrombomodulin, sICAM-3 were higher in CKD5-PD. Further, as compared with CKD5-HD, sICAM-1 was higher in CKD5-PD.

These results of individual serum biomarkers were also reflected by a higher Z-score for ED, but not LGI, in CKD5-PD as compared with CKD5-ND and CKD5-HD."

In addition, we have adjusted the first paragraph of the Discussion (page 29, lines 499-453):

"First, participants ESRD had higher levels of most serum biomarkers of ED and LGI than controls. Second, in participants with CKD5-HD, levels of serum biomarkers of ED and LGI were largely similar to those in CKD5-ND. In contrast, participants with CKD5-PD had higher levels of biomarkers of ED than participants with CKD5-ND and CKD5-HD."

Additional analyses with adjustment for systolic or diastolic blood pressure as well as renin-angiotensin-aldosterone system inhibitor use, HMG CoA use, current smoking and BMI, other import risk factors for ED, were similar. We have added this the Results section (page 16, lines 207-309): "The above results were not materially changed after additional adjustment for systolic or diastolic blood pressure, use of renin-angiotensin-aldosterone system inhibitors, use of HMG-CoA inhibitors, current smoking or BMI (results not shown)."

15\) For the longitudinal analysis we must have separation of PD and HD patients. In addition, in my opinion for dialysis patient regarding the boxplot there is no real differences in all the biomarkers, the test used for statistical significance must be provide explicitly in the results. More interesting than a box blot the authors must provide individual courses of the biomarkers separating HD and PD.

Longitudinal analyses stratified by dialysis modality were in the supplementary analyses. We have now moved these analyses to the main manuscript (Table 2). In addition, we have added individual trajectories to the box plots as requested, both for incident HD patients (Fig 2) and incident PD patients (Fig 3).

Accordingly, the Results section (page 20-21, lines 352-365.) has been adapted as well:

"Figure 2, Figure 3 and S3 Table show the distributions of serum biomarkers of ED and LGI in incident HD and incident PD patients from baseline up to six months after dialysis initiation.

In linear mixed model analyses (Table 3), incident HD patients showed an increase in sVCAM-1, P-selectin and TNF-α from baseline to six months after dialysis initiation, although this change was only borderline statistically significantly for sVCAM-1. In addition, hs-CRP, SAA and IL-6 were lower after six months of follow-up.

In linear mixed model analyses (Table 3), incident PD patients showed a statistically significant increase in sVCAM-1, thrombomodulin, sICAM-1 and sICAM-3 from baseline to six months after dialysis initiation.

In these analyses, statistically significant interaction terms suggested that the courses of P-selectin, sICAM-1, sICAM-3, hs-CRP, SAA and IL-6 were different between incident HD and incident PD patients (Pinteraction \< 0.10)."

Please note that we have reanalyzed the data with the more modern linear mixed model technique. In contrast to repeated measures ANOVA, linear mixed model analysis provides an effect size (here, ratios of concentrations relative to baseline and corresponding 95% confidence interval) in addition to a test of statistical significance, which is presented in the Tables as well. Further, it allows selecting outliers based in regression diagnostics to assess the robustness of results (see below).

This is addressed in the Methods section (page 11, lines 239-249):

"Longitudinal analyses were conducted stratified for incident HD and PD patients, and for kidney transplant recipients. Courses of natural log transformed serum biomarkers of ED and LGI over time following dialysis initiation and kidney transplantation were analyzed with linear mixed models to account for within-person correlations between repeated measurements and missing data. The fixed-effects part contained time as categorical variable (baseline served as reference), and the random-effects parts included a random intercept. The models for incident HD and PD patients also contained an interaction term between time and dialysis modality to test whether courses differ between HD and PD. Models were fitted by restricted maximum likelihood. Regression coefficients were exponentiated to obtain the ratio of (geometric mean) biomarker levels relative to baseline levels."

In addition, we have adjusted the first paragraph of the Discussion (page 29, lines 453-457):

"Third, incident PD patients showed an increase in several serum biomarkers of ED as well, but no convincing change in serum biomarkers of LGI. In contrast, results for incident HD patients were mixed, with an increase in some serum biomarkers of ED and LGI, but a decrease in other biomarkers of LGI."

16\) We must have comparisons with other biological values, like calcium phosphore, bicarbonate urea, creatininemia etc.

We agree that these data would improve the manuscript. Unfortunately, however, these data were not available for the present study, except for serum creatinine, which we have added to Table 1 and S2 Table (please see also our response on comment 13).

17\) For transplantation patients same remarks regarding the representation of data. It could be of interest to indicate the course of values for the 4 patients undergoing dialysis then transplantation the data.

Similar to the presentation of data of dialysis patients, we now provide boxplots with individual trajectories for kidney transplant recipients (Fig 4). In addition, we have reanalyzed the data with linear mixed model analyses as well.

This has been adapted in the Results section (page 24, lines 299-404):

"In linear mixed model analyses (Table 4), kidney transplant recipients showed a statistically significant reduction in sVCAM-1, thrombomodulin, sICAM-3, and TNF-α at three months post-transplantation, which was still present after six months of follow-up. In addition, E-selectin, hs-CRP, SAA and IL-6 were lower at three and six months post-transplantation with similar or even larger magnitudes of effect (i.e., ratios), albeit not statistically significantly and with wide 95% confidence intervals.

In addition, we have adjusted the first paragraph of the Discussion (page 29, lines 457-459):

"Fourth, following kidney transplantation levels of several serum biomarkers of ED and LGI were lower at three months post-transplantation and remained stable at three months thereafter."

Although we agree that a comparison of preemptively and non-preemptively transplanted patients would be interesting, the statistical power of the present study is too low to perform such an analyses and risk of chance findings is high. Instead, we have mentioned this as study limitation (page 32, lines 528-532): "First, statistical power was limited, in particular for the comparison of HD and PD, and for the follow-up of kidney transplant recipients. In addition, the limited number of kidney transplant recipients precluded further stratification, for example to compare participants with preemptive and non-preemptive kidney transplantation."

18\) The additional analysis section is a non sense. All this analysis must be included with main analysis or not discusses. The patients with cyst infection must be definitively excluded.

The correlation plots (page 13, lines 268-274) and stratified analyses for HD vs. PD have now been included in the main analyses (page 13-23, lines 256-392). In addition, the explorative analyses on associations of eGFRCKD-EPI, eGFRresidual, residual urine output and dialysis vintage have been removed, as requested.

We respectfully disagree with the reviewer that the patient with a history of recurring cyst infection should be excluded a priori. Indeed, his most recent episode was six months before study participation and a recent transluminal angioplasty of the patient's dialysis shunt may be an alternative explanation for the increased inflammatory parameters \[2\]. Nevertheless, we agree that this was not clear from our formulation in the previous version of the manuscript. In addition, other participants may have had a rise in inflammatory markers due to an intercurrent infection or inflammatory response as well. Therefore, we have now more performed sensitivity analyses after exclusion of outliers (defined as standardized residuals \< -2 or \> 2 SD on the respective analysis). In general, results were largely similar after exclusion of outliers.

Results (page 27, lines 422-431):

"First, when we excluded outliers (i.e., defined as participants with standardized residuals \< 2 or \> 2 SD) in the cross-sectional linear regression analyses, results were largely similar (S5 Table). Most notable dissimilarities after exclusion of outliers were a smaller difference between CKD5-HD and CKD5-PD for E-selectin; more pronounced differences in SAA between CKD5-HD/CKD5-PD and CKD5-ND; and more pronounced differences in Z-score for LGI between CKD5-PD and CKD5-ND/CKD5-HD.

Second, when we excluded outliers in analyses for the courses of serum biomarkers following dialysis initiation (S6 Table) and kidney transplantation (S7 Table), results were in general similar or somewhat more pronounced."

In addition, we consider the additional adjustments for eGFRresidual, residual urine output, dialysis vintage meaningful: these analyses explore potential explanations for differences between CKD5-HD and CKD5-ND, but may distract from the main message if placed in the main results.

Therefore, we have retained these results as part of the additional analyses (page 27, lines 439-443).

In addition, the use of linear mixed model analyses allowed exploring whether the course of eGFRresidual explained the courses of the serum biomarkers following HD or PD initiation. As we think this question naturally follows from the results, we have added it to the additional analyses (page 28, lines 444-446): "Sixth, additional adjustment for eGFRresidual in linear mixed model analyses attenuated the courses of sVCAM-1 in incident HD and thrombomodulin in incident PD, but did not explain the courses in the other serum biomarkers (S9 Table)."

19\) The discussion will be analyzed after the modification asked for the methods and results.

We have incorporated the results of the stratified analyses of HD and PD throughout the Discussion.

 

Response to the Reviewer \#2

In the present study, the authors compared biomarkers of endothelium dysfunction and low-grade inflammation in controls and in different groups of CKD patients. They show that most biomarkers are higher in CKD patients than in controls, higher in dialysis patients than in non-dialyzed patients and decline after kidney transplantation. Higher levels of serum biomarkers of ED and LGI in CKD patients have been previously shown in the literature. In addition, the data on serum biomarkers after kidney transplantation do not provide new informations and only confirm previous studies.

We thank the reviewer for the time spend to review the manuscript.

1\) The design of the study is complex. It mixes the data of three separate observational studies, but the number of subjects per group is quite low. The characteristics of CKD5-ND and CKD5-D patients are different in terms of origin of end stage renal disease, and presence of diabetes mellitus.

We agree with the reviewer that the design is complex. To help the reader in appreciating the flow of patients of the respective study groups, we have provided a flow diagram in S1 Fig.

The limited study power is addressed as study limitation (page 32, lines 528-532): ". First, statistical power was limited, in particular for the comparison of HD and PD, and for the follow-up of kidney transplant recipients. In addition, the limited number of kidney transplant recipients precluded further stratification, for example to compare participants with preemptive and non-preemptive kidney transplantation."

We agree that characteristics of CKD5-ND and CKD5-D patients differ in terms to cause of ESRD and prevalence of diabetes mellitus. Therefore, comparisons between CKD5-ND and CKD5-D were adjusted for diabetes mellitus. Unfortunately, the number of participants was too low to stratify by cause of ESRD. We added this to the study limitations (page 32, lines 537-540): "Third, the distribution of ESRD causes, with varying prognosis, in this study may hamper comparisons between CKD5-ND and CKD5-D patients, and may limit generalizability. For example, the prevalence of polycystic kidney disease was high, whereas that of diabetic nephropathy was low."

2\) Patients on PD are different from patients on HD (younger, less CVD history, higher residual GFR...), and additional analysis demonstrated differences in biomarkers in these two groups of patients. Therefore,the authors should not include these patients in the same CKD5D group.

We have now provided results stratified by dialysis modality, both for the cross-sectional and longitudinal analyses. The Results section, including Tables and Figures, has been adapted accordingly.

Results (page 13, lines 256-266):

"Population characteristics -- cross-sectional analyses

Thirty-six controls, 43 participants with CKD5-ND, 20 participants with CKD5-HD and 14 participants with CKD5-PD comprised the cross-sectional study population (Table 1; flowchart in S1 Fig). In general, participants with CKD5-ND, CKD5-HD and CKD5-PD were more often men and had a worse CVD risk profile than controls.

Participants with CKD5-HD and CKD5-D more often had diabetes mellitus than those with CKD5-ND. All participants with CKD5-ND and most with CKD5-D had residual urine output. Participants with CKD5-PD slightly younger, less often men, less often had a history of CVD, and had higher residual GFR (eGFRresidual), slightly more fluid overload and shorter dialysis vintage than participants with CKD5-HD, although not all differences were statistically significant in this relatively small study population."

 

Results (page 16, lines 292-306):

"Associations of end-stage renal disease with serum biomarkers of endothelial dysfunction and low-grade inflammation

Table S1 and Figure 1 shows the distributions of serum biomarkers of ED and LGI stratified by participant group.

As compared with controls and after adjustment for age, sex and diabetes mellitus (Table 2), sVCAM-1, E-selectin, thrombomodulin, hs-CRP, SAA, IL-6, and TNF-α were higher in CKD5-ND, CKD5-HD and CKD5-PD. In addition, sICAM-1 was higher in CKD5-ND and CKD5-PD, and sICAM-3 was higher in CKD5-PD only.

These results of individual serum biomarkers were also reflected by higher Z-scores for ED and LGI in CKD5-ND, CKD5-HD and CKD5-PD.

As compared with CKD5-ND and after adjustment for age, sex and diabetes mellitus (Table 2), biomarkers of ED and LGI were in general similar in CKD5-HD. In addition, as compared with both CKD5-ND and CKD5-HD, sVCAM-1, E-selectin, thrombomodulin, sICAM-3 were higher in CKD5-PD. Further, as compared with CKD5-HD, sICAM-1 was higher in CKD5-PD.

These results of individual serum biomarkers were also reflected by a higher Z-score for ED, but not LGI, in CKD5-PD as compared with CKD5-ND and CKD5-HD."

Results (page 20, lines 333-348):

"Population characteristics -- longitudinal analyses

Thirty-four participants with CKD5-ND who initiated dialysis (18 HD, 16 PD), 6 with CKD5-ND who received a kidney transplant, and 5 on chronic dialysis who received a kidney transplant were included in the longitudinal analyses (S2 Table; S1 Fig). In addition, 4 participants who initiated dialysis and later received a kidney transplant were included as kidney transplant recipients as well.

As compared with kidney transplant recipients, incident HD and PD patients were older (65.1 ±12.0 and 57.1 ±12.1 years vs. 51.6 ±12.8 years) and more often had a history of CVD (38.9% and 31.2% vs. 13.3%). In addition, incident HD patients were more often men (83.3% vs. 60.0%). Estimated GFRCKD-EPI was similar and all participants had residual urine output. Incident dialysis patients on PD were younger (57.1 ±12.1 vs. 65.1 ±12.0 years) and less often men (56.2% vs. 83.3%), and had lower BMI (23.5 ±3.0 vs. 26.6 ±3.8 kg/m2), higher diastolic blood pressure (87.3 ±16.0 vs. 77.4 ±9.2 mmHg), and less fluid overload (0.8 ±1.4 vs. 1.9 ±2.4 L), although not all differences were statistically significant. One PD patient switched to HD during follow-up."

Results (page 20-21, lines 350-365):

"Courses of serum biomarkers of endothelial dysfunction and low-grade inflammation following dialysis initiation

Fig 2, Fig 3 and S3 Table provide data on the distributions and individual trajectories of serum biomarkers of ED and LGI in incident HD and incident PD patients from baseline up to six months after dialysis initiation.

In linear mixed model analyses (Table 3), incident HD patients showed an increase in sVCAM-1, P-selectin and TNF-α from baseline to six months after dialysis initiation, although this change was only borderline statistically significantly for sVCAM-1. In addition, hs-CRP, SAA and IL-6 were lower after six months of follow-up.

In linear mixed model analyses (Table 3), incident PD patients showed a statistically significant increase in sVCAM-1, thrombomodulin, sICAM-1 and sICAM-3 from baseline to six months after dialysis initiation.

In these analyses, statistically significant interaction terms suggested that the courses of P-selectin, sICAM-1, sICAM-3, hs-CRP, SAA and IL-6 were different between incident HD and incident PD patients (Pinteraction \< 0.10)."

In addition, we have adjusted the first paragraph of the Discussion (page 29, lines 448-459):

"This study on ED and LGI on individuals transitioning from untreated ESRD to renal replacement therapy had four main findings. First, participants ESRD had higher levels of most serum biomarkers of ED and LGI than controls. Second, in participants with CKD5-HD, levels of serum biomarkers of ED and LGI were largely similar to those in CKD5-ND. In contrast, participants with CKD5-PD had higher levels of biomarkers of ED than participants with CKD5-ND and CKD5-HD. Third, incident PD patients showed an increase in several serum biomarkers of ED as well, but no convincing change in serum biomarkers of LGI. In contrast, results for incident HD patients were mixed, with an increase in some serum biomarkers of ED and LGI, but a decrease in other biomarkers of LGI. Fourth, following kidney transplantation levels of several serum biomarkers of ED and LGI were lower at three months post-transplantation and remained stable at three months thereafter."

Further, we have incorporated the results of analyses stratified by dialysis modality throughout the Discussion.

3\) The choice of statistical analyses is not clear. Why do the authors compare the data of biomarkers between groups with linear regression analysis and not with tests for group comparison like ANOVA or Mann Whitney? In addition, why do the authors use a natural log transformation to perform statistical test on the levels of serum biomarkers? How is the distribution of the data (normal or not)?

We chose to analyze between-group differences with linear regression analyses as this technique allows adjustment for potential confounders (here a limited selection of age, sex and diabetes mellitus given the low statistical power).

The distribution of serum biomarkers were positively skewed. Therefore, these values were natural log transformed to obtained acceptably normally distributed residuals of the regression analyses.

We have now clarified this in the Methods (page 10, lines 218-224): "Differences in individual serum biomarkers of ED and LGI between CKD5-ND, CKD5-HD, CKD5-PD and controls were evaluated with linear regression analyses to allow adjustment for potential confounders. Levels of serum biomarkers were positively skewed and, therefore, natural log transformed to obtain acceptably normally distributed residuals. The regression coefficients were exponentiated to obtain the ratio of (geometric mean) levels of the serum biomarkers in CKD5-ND, CKD5-HD and CKD5-PD relative to controls and among ESRD groups."

Please note that we have reanalyzed the data with the more modern linear mixed model technique, which in contrast to repeated measures ANOVA, provides an effect size (here, ratios of concentrations relative to baseline and corresponding 95% confidence interval) in addition to a test of statistical significance, which is presented in the Tables as well.

This is addressed in the Methods section (page 11, lines 239-249):

"Longitudinal analyses were conducted stratified for incident HD and PD patients, and for kidney transplant recipients. Courses of natural log transformed serum biomarkers of ED and LGI over time following dialysis initiation and kidney transplantation were analyzed with linear mixed models to account for within-person correlations between repeated measurements and missing data. The fixed-effects part contained time as categorical variable (baseline served as reference), and the random-effects parts included a random intercept. The models for incident HD and PD patients also contained an interaction term between time and dialysis modality to test whether courses differ between HD and PD. Models were fitted by restricted maximum likelihood. Regression coefficients were exponentiated to obtain the ratio of (geometric mean) biomarker levels relative to baseline levels."

4\) Identical data are presented several times, in different figures/tables. For example, Figure 2 and Table 3 provides the same informations, data in Table 3 are also in S1 Table etc...

We have adapted the tables to reduce overlapping information in the main manuscript. However, we think that some readers prefer tabulated data on serum biomarkers over boxplots. Therefore, we have provided such tables as supplementary data (S1 Table, S3 Table and S4 Table).

5\) For a better understanding, the authors should add the symbols of p values on figures and tables. In particular, the p values between CKD5-ND and CKD5D should be mentioned in Table 1.

We have added symbols for P values for comparisons among patient groups to Table 1 as requested and added this to the Methods section as well.

Methods (page 10, lines 206-210):

"Unadjusted post-hoc comparisons of characteristics of participant groups were performed with the independent Student t-test for normally distributed data, Dunn's test for non-normally distributed data and Fisher's exact test for categorical data if a one-way analysis of variance (ANOVA) test, Kruskal-Wallis test and Fisher's exact test, respectively, indicated an overall difference between groups."

Legend Table 1 (page 15, lines 286-288): "† P value \< 0.05 vs. controls; ‡ P value \< 0.05 vs. CKD5-ND; ¶ P value \< 0.05 vs. CKD5-HD. Unadjusted post-hoc comparisons of controls, CKD5-ND, CKD5-HD and CKD5-PD were performed with the independent Student t-test for normally distributed data, Dunn's test for non-normally distributed data and Fisher's exact test for categorical data if an ANOVA, Kruskal-Wallis test and Fisher's exact test, respectively, indicated an overall difference between groups (†, P value \< 0.05 vs. controls; ‡ P value \< 0.05 vs. CKD5-ND; ¶ P value \< 0.05 vs. CKD5-HD)."

Legend S2 Table: "¶ P value \< 0.05 vs. CKD5-HD based on Student's t test for normally distributed data, Wilcoxon rank sum test for non-normally distributed data and Fisher's exact test for categorical data."

In addition, we have added figures for P values to Fig 1-4, as requested.

6\) In table 3, an entire column is NA, please remove the column. In S1 Table, dialysis vintage and KT/V are NA, please remove the lines.

We have adapted the Tables as requested. Please note that former Table 3 is now S3 Table and S4 Table, and that former S1 Table is now S2 Table. 

Response to Reviewer \#3

Manuscript is well written. Only minor suggestions to improve the manuscript.

We thank the reviewer for the compliment and the time spend to review the manuscript.

1\) Please try to avoid the use of () in the descriptive sentences in academic writing "This risk is not (completely) mitigated by renal replacement therapy"

We have removed the brackets as requested.

Abstract (page 2, lines 39-40): "This risk is not (completely) mitigated by renal replacement therapy."

Methods (page 9, lines 182-184): "History of diabetes mellitus and cardiovascular disease, and medication use were based on self-report for healthy controls and the health record for patients."

2\) "Only data of their first study was analyzed" "of" should be "from"

We have changed this accordingly (page 6, lines 129): "Only data from their first study was analyzed."

3\) Also, I suggest the investigators to may improve the introduction/discussion by going over very nice review on this topic PMID: 30607032 Nat Rev Nephrol. 2019 Feb;15(2):87-108. doi: 10.1038/s41581-018-0098-z

We thank the reviewer for the recommended review. As the review is mostly on the effects of ED at the renal level instead of systemic ED, we briefly mention this in the Introduction (page 4, lines 80-82): "In addition, ED and LGI interact at the renal level and may contribute to the development and progression of renal injury, as elegantly described recently\[3\]."

In addition, we added this review as a reference to our discussion on the causal mechanisms of ED and LGI in ESRD (page 29-30, lines 470-474): "The causal mechanisms of ED and LGI in ESRD are likely multifactorial and may include exposure to traditional CVD risk factors, oxidative stress, fluid and sodium overload, gut dysbiosis, accumulation of uremic toxins\[3-5\], and turbulent flow\[6\] due to the hyperdynamic circulation after arteriovenous shunt creation\[7\]. In addition, ED and LGI may be interrelated\[8\] as illustrated by the correlation matrix."

 

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

We have adapted the manuscript according to PLOS ONE's style requirements. The heading of the section listing supporting information was changed to Supporting information (page 38, lines 691).

2\. In your Methods section, please provide additional information regarding the source of donated organs received by the patients in the study. Please specify whether the study involved the use of donated tissue/organs from any vulnerable populations, and provide information on the consent given by the donor or their next of kin. Examples of vulnerable populations include prisoners, subjects with reduced mental capacity due to illness or age, and children. If such a population was used, please ensure you have describe the population and justify the decision to use tissue/organ donations from this group. If not, please state in your Ethics Statement, \'None of the transplant donors were from a vulnerable population and all donors or next of kin provided written informed consent that was freely given.

We have added this to the Methods section (page 7, lines 144-146): In addition, none of the transplant donors were from a vulnerable population and all donors or next of kin provided written informed consent that was freely given.

Donors are carefully provided information and the screening procedure of a potential donor is essential in living kidney donation. Therefore, potential donors are screened and evaluated according to the national Guideline 'Evaluation of potential donors for living kidney donation' of the Dutch Transplant Society and the Dutch Kidney Transplantation Advisory Committee. These guidelines are based on the 'The United Kingdom Guidelines for Living Donor Kidney Transplantation' of the British Transplantation Society and the Renal Association (see link)

<https://bts.org.uk/wp-content/uploads/2018/01/BTS_LDKT_UK_Guidelines_2018.pdf>.

All donors have been informed about the risks and consequences of kidney donation, and before donation written informed consent is needed. Independent psychosocial evaluation is mandatory to be sure that the potential donor is well informed and understands the risks of donation and a further life with a reduced eGFR.
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We will update your Data Availability statement on your behalf to reflect the information you provide.

Not applicable.

5\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.
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